Abiraterone and Increased Survival in Metastatic Prostate Cancer
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index; 17 of the 40 sources its claims cite were checked for support.
Abstract
BACKGROUND: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS: We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS: After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group. CONCLUSIONS: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 7 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A unique molecular alteration described in castration-resistant prostate cancer is the up-regulation of androgen biosynthesis enzymes, leading to an increase in intratumoral androgen concentrations, which can exceed the levels measured in the blood.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [7] matched to “Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance” (2004) source
- Partly supportedcites [8] matched to “Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer” (2006) sourceExperimental — accuracy not yet measured
The Abstract and Discussion (page numbers unavailable) report increased expression of androgen-metabolism genes in androgen-independent prostate cancer and propose enhanced intracellular conversion of adrenal androgens as a mechanism for substantial tissue androgen levels. The paper does not state that intratumoral androgen concentrations exceed blood levels; its tissue comparison is with normal or nonneoplastic prostate. (LLM, conf=0.88)
- Partly supportedcites [9] matched to “Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth” (2008) sourceExperimental — accuracy not yet measured
The Results report up-regulated transcripts for androgen-biosynthesis enzymes in castration-resistant metastases and say tumor testosterone concentrations exceeded equivalent concentrations in the patients’ serum. But the Discussion says the processes sustaining intratumoral androgens have yet to be determined and proposes enzyme modulation as a possible mechanism; it does not establish that the up-regulation caused the higher concentrations. No page number is available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Treatment with abiraterone acetate did not appear to increase the risk of metabolic changes or symptoms associated with chronic androgen deprivation.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Could not verifycites [42] matched to “Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer” (2010) sourceExperimental — accuracy not yet measured
The Methods passage describes GnRH agonists, orchiectomy, and oral antiandrogens, but does not identify abiraterone acetate as a treatment studied. The Results and Discussion address diabetes and cardiovascular outcomes for those treatments, not metabolic changes or symptoms during abiraterone treatment. Searches for “abiraterone acetate” and the claimed metabolic changes and symptoms found no passage addressing that specific claim. (LLM, conf=0.77)
- Could not verifycites [43] matched to “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology” (2010) sourceExperimental — accuracy not yet measured
The 'Adverse Effects of ADT' section describes metabolic changes associated with androgen-deprivation therapy generally, but does not assess abiraterone acetate. Searches for 'abiraterone acetate' and 'symptoms associated with chronic androgen deprivation' found no passage addressing whether abiraterone increases those risks. (LLM, conf=0.76)
- Not checked yetcites [44] matched to “Management of Complications of Prostate Cancer Treatment” (2008) source
- Not checked yetcites [45] matched to “Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer” (2004) source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These results show that continued androgen-receptor signaling contributes to disease progression”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Not checked yetcites [2] matched to “Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis” (2005) source
- Supportedcites [10] matched to “Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?” (2009) source
The Abstract of the Attard et al. (2009) Cancer Cell preview states that 'clinical data from abiraterone acetate and MDV-3100 confirm continued androgen receptor (AR) addiction in a significant proportion of castration-resistant prostate cancers,' and the Main Text adds that 'the growth of the majority of cancer cells in many patients with cancers recurring after castration remains dependent on the AR signaling axis,' with nuclear AR expression persisting in metastases and AR transcriptional activity described as 'required for prostate cancer progression' (Hormone-Driven Oncogenesis). The conclusion reiterates that a significant proportion of CRPC finds AR signaling 'a hard habit to break.' This covers the claim's substance — persistent AR signaling contributing to progression in metastatic CRPC — though the source phrases it as addiction/persistence in a significant proportion rather than in all patients. (LLM, conf=0.88)
- Not checked yetcites [31] matched to “Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling” (2011) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In phase 1–2 trials, treatment with abiraterone acetate, either as a single agent or in combination with low-dose glucocorticoids such as prednisone, resulted in significant antitumor activity among both patients with progressing castration-resistant prostate cancer who had not received chemotherapy and those who had received chemotherapy.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
The Abstract Patients and Methods (p.1) and Introduction state this phase I/II trial enrolled castrate, chemotherapy-naive CRPC patients only, and the PATIENTS AND METHODS > Patients section explicitly excludes 'Patients who had previously received cytotoxic chemotherapy or a radiopharmaceutical'; the antitumor activity figures (≥50% PSA decline in 67% of 42, RECIST partial responses in 9/24, Abstract Results) therefore apply solely to the chemotherapy-naive population. The low-dose glucocorticoid component is supported in that the study prospectively added dexamethasone 0.5 mg/d at progression and reversed resistance in 33% of patients (Abstract Results; Discussion). What this source does not support is the post-chemotherapy arm of the claim: the Discussion mentions only that a phase III study of abiraterone plus prednisone in docetaxel-treated patients 'is now being evaluated,' with no results reported here. (LLM, conf=0.85)
- Supportedcites [16] matched to “Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids” (2010) source
In the body of this correspondence (section 'Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids'), the authors open by summarising the three multicenter phase I/II studies of abiraterone acetate in CRPC (chemotherapy-naive Ryan et al, and the post-docetaxel Reid et al and Danila et al studies listed in their References) and state that their prechemotherapy data 'confirmed the significant antitumor activity of abiraterone acetate' (radiologic regression, PSA and circulating tumour cell decreases), that the combination with low-dose corticosteroids (dexamethasone/prednisone) gave 'durable secondary tumor responses... in 25% of patients', and close by affirming 'the significant and durable antitumor activity and the satisfactory safety profile of abiraterone acetate at 1,000 mg daily'. Low-dose prednisone is explicitly named. This source is correspondence reporting/summarising those trials rather than a primary trial report, but it states every element attributed to it here. (LLM, conf=0.82)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy is a single phase I trial, and it confirms significant antitumor activity (PSA declines ≥30%/≥50% in 66%/57% of 21 patients, RECIST partial responses in 5 of 8) in chemotherapy-naive CRPC (Antitumor Activity section), with low-dose dexamethasone 0.5 mg/d added at progression reinducing sensitivity in 4 of 15 patients (Reversal of Resistance section). However, the post-chemotherapy arm and the phase II results are not reported here: the Discussion (B2 C1 C2) states only that these findings 'have led to the phase II evaluation... in both chemotherapy-naïve and docetaxel-treated patients... data from this evaluation will be reported soon,' and the Patients section explicitly excluded men previously treated with chemotherapy. Prednisone is not the glucocorticoid used in this paper (dexamethasone was), so the 'phase 1-2 trials... both chemotherapy-naive and post-chemotherapy' scope is not carried by this source. (LLM, conf=0.78)
- Supportedcites [18] matched to “Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer” (2010) source
Our copy covers every element of the summary sentence. The Abstract and Results describe this phase II trial of abiraterone acetate 1,000 mg daily with low-dose prednisone 5 mg twice daily in 58 men with progressive metastatic CRPC after docetaxel failure, reporting significant antitumor activity (confirmed ≥ 50% PSA decline in 36%, partial responses in 4/22 RECIST-evaluable patients, ECOG improvement in 28%). The Introduction states that 'Significant antitumor effects were seen in patients with progressive CRPC who had not received prior chemotherapy' (citing the phase I trial, Attard 2008, and the phase II chemo-naive AA-plus-prednisone study, Ryan 2009) and that 'In a separate trial, we showed significant antitumor effects of abiraterone acetate (AA) monotherapy in this patient group' (post-docetaxel, Reid/Danila), i.e. activity with AA alone as well as with low-dose steroid, in both chemotherapy-naive and post-chemotherapy settings. The Discussion likewise frames this as 'the second trial showing the activity of AA in patients ... who have progressed on chemotherapy.' (LLM, conf=0.85)
- Partly supportedcites [19] matched to “Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate” (2010) sourceExperimental — accuracy not yet measured
Our copy directly supports the trial/patient-population part: the Conclusion (p. 1) and DISCUSSION (p. 5) state that abiraterone acetate 1,000 mg had significant antitumor activity in post-docetaxel CRPC (≥50% PSA declines in 51%, with radiologic, symptomatic and CTC support), and the INTRODUCTION (p. 2) plus DISCUSSION (p. 6) report the authors' own phase I and phase II pre-docetaxel (chemotherapy-naïve) studies as showing abiraterone 'well tolerated and active'. What our copy does not support is the efficacy attribution to a glucocorticoid combination: low-dose glucocorticoids (and eplerenone) appear only as management of mineralocorticoid-excess toxicities (Treatment and Procedures, p. 3; Safety, p. 5; DISCUSSION, p. 6), the trial itself was single-agent abiraterone, and prednisone co-administration is mentioned only as the design of the subsequent phase III trial (DISCUSSION, p. 5), not as a phase 1-2 activity result. (LLM, conf=0.78)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) supports only part of the sentence: the DISCUSSION (p. 1) states 'Abiraterone acetate has significant activity in patients with CRPC, as evidenced by a PSA response rate of 58% in this phase I trial,' and RESULTS/Efficacy report confirmed ≥50% PSA declines in 55%-58% of men with chemotherapy-naïve progressive CRPC, including 47% of those with prior ketoconazole. However, this is a single-agent phase I dose-escalation trial only — 'Prior chemotherapy for prostate cancer was not allowed' (Major Eligibility Criteria), and the DISCUSSION states the exclusion of prior-chemotherapy patients was intentional, with 'ongoing studies...evaluating abiraterone in patients with both chemotherapy-refractory and chemotherapy-naïve CRPC,' so the post-chemotherapy activity attributed here is not from this paper. Glucocorticoids were also not part of the tested regimen: prednisone/corticosteroids were used reactively to manage mineralocorticoid toxicity, and the authors only 'suggest that a low dose of a corticosteroid, such as prednisone, be administered with abiraterone acetate in future studies'; the DISCUSSION notes 'the impact of concurrent prednisone on response proportion and durability...is not known.' (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile observed in the group of patients who received abiraterone acetate was similar to that observed in earlier clinical studies.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
Our copy details the safety profile of the 1,000-mg abiraterone acetate group in RESULTS > Safety Profile (secondary mineralocorticoid excess: hypokalemia 88%, hypertension 40%, fluid overload 31%, managed with eplerenone; grade 3 transaminase elevation in 2 patients; grade 1 headaches/joint aches) and calls it 'effective, well-tolerated' in the DISCUSSION, so the first half of the claim is grounded. However, no passage states that this profile was 'similar to that observed in earlier clinical studies'; the only cross-study safety remarks compare abiraterone with ketoconazole trials (grade >=3 toxicities in up to 30% of patients, all requiring hydrocortisone) and explicitly caution that 'it is difficult to make any comparisons.' The prior abiraterone phase I experience is referenced (ref 15) as having identified the 1,000-mg dose, not as a matched safety comparison. The comparative/similarity element is therefore unsupported by our copy. (LLM, conf=0.68)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy documents this trial's own safety profile (Safety and Tolerability: dose escalation to 2,000 mg achieved, no treatment-related grade 3 or 4 toxicities, hypertension/hypokalemia/edema controlled with eplerenone; DISCUSSION: toxicities predominantly due to secondary mineralocorticoid excess), and the INTRODUCTION notes that first-in-man studies reported abiraterone acetate was safe when given daily for 12 days to men with prostate cancer. However, no passage compares the two or states the profiles were similar; the only 'similar' statement in the paper is of hypertension incidence across dose levels within this study, and the DISCUSSION frames this as 'the first study to demonstrate that selective and continuous inhibition of CYP17 is safe', with the earlier clinical experience being short-course dosing in noncastrate men. The comparative element of the claim ('similar to that observed in earlier clinical studies') is therefore not supported by this source. (LLM, conf=0.65)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) describe their own safety findings as acceptable and consistent with expected CYP17 inhibition (DISCUSSION: 'The adverse event and steroid endocrine profiles were consistent with anticipated outcomes of selective CYP17 inhibition'; well tolerated through 1,000 mg/d with no MTD and no toxicity difference by prior ketoconazole exposure, DISCUSSION). However, the only external comparison our copy makes is to a CONCURRENT study, not to earlier clinical studies: RESULTS (Dose Escalation) states 'These findings paralleled a concurrent study with abiraterone acetate.' The claim's framing of similarity to 'earlier clinical studies' is therefore not supported by this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
23 more claims · 3 with their cited sources checked
Create a free account to see all 50 claims and to verify the 23 references still open.
- It may state two separate claims as one. 10
- The quote only partly states this claim. 3
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abiraterone acetate is an orally active prodrug of abiraterone, a potent P450c17 inhibitor (316) indicated for treatment of castration-resistant prostate cancer (317, 318).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [317]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [20]
In the citing paper
“Abiraterone is a potent CYP17A1 inhibitor that efficiently inhibits testosterone production120 and is used to treat prostate cancer.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [120]
In the citing paper
“Additionally, androgen biosynthesis from C21 precursors can be reduced by CYP17A1 inhibition with abiraterone as successfully applied for the treatment of CRPC (Attard et al., 2008, de Bono et al., 2011, James et al., 2017).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as de Bono et al., 2011
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 3×
“Bone pain 194 (25) 42 (5) 2 (<1) 110 (28) 25 (6) 4 (1)”
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241 · cited 1×
“Fluid retention and edema 241 (31) 16 (2) 2 (<1) 88 (22) 4 (1) 0”
Self-citationde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182 · cited 2×
“Nausea 233 (30) 12 (2) 1 (<1) 124 (32) 10 (3) 0”
Self-citationDevelopment of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Cited by
Items 601–700 of 1,010
Illuminating cytochrome P450 binding: Ru( ii )-caged inhibitors of CYP17A1
Li, A., Yadav, R., White, J. K., Herroon, M. K., Callahan, B. P., Podgorski, I., Turró, C., Scott, E. E., & Kodanko, J. J. (2017) · Chemical Communications · doi:10.1039/c7cc01459g · Cited by 77
Accelerating precision medicine in metastatic prostate cancer
Mateo, J., McKay, R. R., Abida, W. M., Aggarwal, R. R., Alumkal, J. J., Alva, A. S., Feng, F. Y.-C., Gao, X. Y., Graff, J. N., Hussain, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00141-0 · Cited by 83
Self-citationCurrent and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Henriquez, I., Roach, M., Morgan, T. M., Bossi, A., Gómez, J., Abuchaibe, O., & Couñago, F. (2021) · Biomedicines · doi:10.3390/biomedicines9091247 · Cited by 85
“Prednisone is a synthetic corticosteroid metabolized to prednisolone (active form) in the liver [16].”
BackgroundMethodTubulin: An Example of Targeted Chemotherapy
Seligmann, J. F., & Twelves, C. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.217 · Cited by 81
Matsumoto, H., Yamamoto, Y., Shiota, M., Kuruma, H., Beraldi, E., Matsuyama, H., Zoubeidi, A., & Gleave, M. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0359 · Cited by 75
“More recently, the CYP17 inhibitor abiraterone (10) and the AR antagonist MDV3100 (11) have prolonged survival and are rapidly changing the CRPC treatment landscape.”
BackgroundUtility of FDG‐PET in clinical neuroendocrine prostate cancer
Spratt, D. E., Gavane, S. C., Tarlinton, L., Fareedy, S. B., Doran, M. G., Zeléfsky, M. J., & Osborne, J. R. (2014) · The Prostate · doi:10.1002/pros.22831 · Cited by 74
Li, J., Tian, Y., Zhao, L., Wang, Y., Zhang, H., Xu, D., Zhao, X., & Li, Y. (2015) · Asian Journal of Andrology · doi:10.4103/1008-682x.169997 · Cited by 78
AR-Signaling in Human Malignancies: Prostate Cancer and Beyond
Schweizer, M. T., & Yu, E. Y. (2017) · Cancers · doi:10.3390/cancers9010007 · Cited by 77
Francini, E., Gray, K. P., Shaw, G. K., Evan, C. P., Hamid, A. A., Perry, C. E., Kantoff, P. W., Taplin, M.-E., & Sweeney, C. J. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0121-2 · Cited by 74
Ellis, L., Ku, S., Ramakrishnan, S., Lasorsa, E., Azabdaftari, G., Godoy, A., & Пили, Р. (2013) · Oncotarget · doi:10.18632/oncotarget.1314 · Cited by 78
“The second line cabazitaxel [1], the immunotherapy sipuluecel-T [2], the androgen synthesis inhibitor abiraterone acetate [3] the AR antagonist enzalutamide [4] and the alpha particle emitter radium-223 [5] have all received recent FDA approval for the treatment of advanced PCa.”
The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
Zheng, Z., Li, J., Liu, Y., Shi, Z., Xuan, Z., Yang, K., Xu, C., Bai, Y., Fu, M., Xiao, Q., et al. (2022) · Cancers · doi:10.3390/cancers14194877 · Cited by 82
“Enzalutamide (ENZ) is the second-generation ARSI by the FDA approval and the most important new drug of endocrine therapies for CRPC [7].”
BackgroundMeulenbeld, H. J., Bleuse, J. P., Vinci, E. M., Raymond, É., Vitali, G., Santoro, A., Dogliotti, L., Berardi, R., Cappuzzo, F., Tagawa, S. T., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11404.x · Cited by 77
Self-citationODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Fizazi, K. S., Albiges, L. K., Loriot, Y., & Massard, C. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1081566 · Cited by 79
Self-citationXu, X. S., Ryan, C. J., Stuyckens, K., Smith, M. R., Saad, F., Griffin, T. W., Park, Y. C., Yu, M. K., Vermeulen, A., Poggesi, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1549 · Cited by 71
Self-citationSmith, M. R., Rathkopf, D. E., Mulders, P., Carles, J., Poppel, H. V., Li, J., Kheoh, T. S., Griffin, T. W., Molina, A., & Ryan, C. J. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.07.004 · Cited by 78
Self-citationPersistent androgen receptor addiction in castration-resistant prostate cancer
Schweizer, M. T., & Yu, E. Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0225-2 · Cited by 85
“on the basis that it significantly prolongs survival in both the pre- and postdocetaxel spaces [6, 7, 32].”
BackgroundWnt signaling in castration-resistant prostate cancer: implications for therapy.
Yokoyama, N. N., Shao, S., Hoang, B. H., Mercola, D., & Zi, X. (2014) · PubMed · Cited by 75
Ho, Y., & Dehm, S. M. (2017) · Endocrinology · doi:10.1210/en.2017-00109 · Cited by 79
“These findings served as the basis for targeting intracrine androgen synthesis with abiraterone, a steroidal inhibitor of the 17a-hydroxylase and 17,20-lyase activities of the CYP17A1 androgen synthesis enzyme expressed in testes, adrenal glands, and prostate cancer cells (8, 9) (Fig.”
BackgroundBarnard, M., Quanson, J. L., Mostaghel, E., Pretorius, E., Snoep, J. L., & Storbeck, K.-H. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.06.013 · Cited by 72
Porter, B. A., Ortiz, M. A., Bratslavsky, G., & Kotula, L. (2019) · Cancers · doi:10.3390/cancers11121852 · Cited by 91
“Treatment with abiraterone has been shown to extend cancer free‐survival for 35 months in patients not previously treated with chemotherapy [59].”
BackgroundUnequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
Groot, C. A. U., Heine, R. J. S. D., Krol, M., & Verweij, J. (2020) · Cancers · doi:10.3390/cancers12082313 · Cited by 76
“of patients in need for abiraterone and ipilimumab we used the dosing and the median number of cycles from the clinical trials [23,24].”
MethodRozet, F., Mongiat-Artus, P., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mathiéu, R., Ploussard, G., Renard‐Penna, R., et al. (2020) · The French Journal of Urology · doi:10.1016/s1166-7087(20)30752-1 · Cited by 87
Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection
Hahn, V. S., Zhang, K. W., Sun, L., Narayan, V., Lenihan, D. J., & Ky, B. (2021) · Circulation Research · doi:10.1161/circresaha.121.318223 · Cited by 76
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
Roudsari, N. M., Lashgari, N., Momtaz, S., Abaft, S., Jamali, F., Safaiepour, P., Narimisa, K., Jackson, G., Bishayee, A., Rezaei, N., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081195 · Cited by 75
“In a phase II study, a combination of bicalutamide, everolimus, and salinomycin, as mTORC1 and AR inhibitors, could improve mCRPC by targeting the PI3K/Akt pathway [110,111].”
BackgroundInfluentialYu, E. Y., Piulats, J. M., Gravis, G., Fong, P. C. C., Todenhöfer, T., Laguerre, B., Arranz, J. Á., Oudard, S. M., Massard, C., Heinzelbecker, J., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.08.005 · Cited by 78
Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review
Mokhosoev, I. M., Astakhov, D. V., Terentiev, A. A., & Moldogazieva, N. T. (2024) · Cells · doi:10.3390/cells13231958 · Cited by 84
Hernandez-Hoyos, G., Sewell, T., Bader, R., Bannink, J., Chenault, R. A., Daugherty, M., Dasovich, M., Fang, H., Gottschalk, R., Kumer, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0242 · Cited by 72
The role of ketoconazole in current prostate cancer care
Patel, V. G., Liaw, B. C.-H., & Oh, W. K. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0077-y · Cited by 79
Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway
Castaño, P. R., Parween, S., & Pandey, A. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184606 · Cited by 72
Immunotherapy for prostate cancer: recent developments and future challenges
Schweizer, M. T., & Drake, C. G. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9479-8 · Cited by 80
Nussbaum, N., George, D. J., Abernethy, A. P., Dolan, C. M., Oestreicher, N., Flanders, S., & Dorff, T. B. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2015.42 · Cited by 71
CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer
Bastos, D. A., & Antonarakis, E. S. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1427068 · Cited by 73
“AR-signaling (ARS) inhibitors (abiraterone [4,5] and enzalutamide [6,7]), taxane chemotherapy with docetaxel [8] and caba-”
BackgroundUo, T., Sprenger, C. C. T., & Plymate, S. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580617 · Cited by 88
“Although most patients with PCa initially respond to AR inhibition, they eventually develop castration-resistant PCa (CRPC) (36, 90, 91).”
BackgroundMacLean, D. B., Shi, H., Faessel, H. M., & Fred Saad, C. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2770 · Cited by 73
“n 24 8 30 10 44 22 30 8 Bradycardia 19 (79) 7 (88) 27 (90) 9 (90) 33 (75) 17 (77) — — Headache 1 (4) — 7 (23) 2 (20) 8 (18) 4 (18) 11 (37) 4 (50) Hot flush 1 (4) — 7 (23) — 19 (43) 2 (9) 11 (37) — AV block first degree 1 (4) — 6 (20) — — — — — Decreased libido — — 5 (17) — — — — — Prolonged QTc 1 (4) — 4 (13) — 7 (16)…”
Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness
Ohno, Y., Nakashima, J., Izumi, M., Ohori, M., Hashimoto, T., & Tachibana, M. (2012) · World Journal of Urology · doi:10.1007/s00345-012-0977-z · Cited by 76
“Recently, several new agents such as cabazitaxel and abiraterone acetate have been approved in the United States and Europe [3, 4].”
BackgroundCurrent approaches to incorporation of radium-223 in clinical practice
Parker, C. C., Heidenreich, A., Nilsson, S. F., & Shore, N. D. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-017-0020-y · Cited by 76
“The patient should also be made aware that they may eventually receive all other available therapies as needed to control their disease and increase survival over the course of treatment (including docetaxel [56], abiraterone [21], enzalutamide [17], cabazitaxel [19], and sipuleucel-T [57]) whether in combination or s…”
BackgroundResistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
Antonarakis, E. S., & Boudadi, K. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34534 · Cited by 110
Imaging for Metastasis in Prostate Cancer: A Review of the Literature
Turpin, A., Girard, E., Baillet, C., Pasquier, D., Olivier, J., Villers, A. A., Puech, P., & Penel, N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00055 · Cited by 75
Human Cytochrome P450 17A1 Conformational Selection
Estrada, D. F., Skinner, A. L., Laurence, J. S., & Scott, E. E. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.560144 · Cited by 72
“Its inhibition by the active drug abiraterone for metastatic castration-resistant prostate cancer (24) recently provided an exciting new option for treating the second leading cause of cancer death in United States men (25).”
BackgroundMini-review: Foldosome regulation of androgen receptor action in prostate cancer
Cano, L. Q., Lavery, D. N., & Bevan, C. L. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.023 · Cited by 82
Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer
Yasumizu, Y., Miyajima, A., Kosaka, T., Miyazaki, Y. J., Kikuchi, E., & Oya, M. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.07.101 · Cited by 74
ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells
Powell, K., Semaan, L., Conley‐LaComb, M. K., Asangani, I. A., Wu, Y.-M., Ginsburg, K., Williams, J. L., Squire, J. A., Maddipati, K. R., Cher, M. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2352 · Cited by 77
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone
Burgio, S. L., Conteduca, V., Menna, C., Carretta, E., Rossi, L., Bianchi, E., Kopf, B., Fabbri, F., Amadori, D., & Giorgi, U. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0071 · Cited by 74
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Andriole, G. L. (2012) · Yearbook of Urology · doi:10.1016/j.yuro.2012.07.007 · Cited by 70
Cardiac arrhythmia considerations of hormone cancer therapies
Barber, M., Nguyen, L. S., Wassermann, J., Spano, J., Funck‐Brentano, C., & Salem, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz020 · Cited by 69
The androgen receptor regulates a druggable translational regulon in advanced prostate cancer
Liu, Y., Horn, J. L., Banda, K., Goodman, A. Z., Lim, Y., Jana, S., Arora, S., Germanos, A. A., Wen, L., Hardin, W. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw4993 · Cited by 71
“We evaluated 29 CRPC LuCaP patient-derived xenograft (PDX) models for AR and 4EBP1 protein abundance.”
BackgroundInfluentialPSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer
Burgio, S. L., Conteduca, V., Rudnas, B., Carrozza, F., Campadelli, E., Bianchi, E., Fabbri, P., Montanari, M., Carretta, E., Menna, C., et al. (2014) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.06.010 · Cited by 68
“Abiraterone is a new hormonal therapy that has shown some benefit in the survival of patients with CRPC; PFS has been positively associated with the magnitude of PSA level decline.(5-7,19) However, in those studies, serum PSA levels were monitored every 2 to 3 months, so the PSA flare phenomenon has not been investiga…”
BackgroundMethodInfluentialPetrick, J. L., Hyland, P. L., Caron, P., Falk, R. T., Pfeiffer, R. M., Dawsey, S. M., Abnet, C. C., Taylor, P. R., Weinstein, S. J., Albanes, D., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy082 · Cited by 69
MacLean, D. B., Matsui, H., Suri, A., Neuwirth, R., & Colombel, M. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4236 · Cited by 79
Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor
Bryce, A. H., & Ryan, C. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.275 · Cited by 71
“24) Chemotherapy and ketoconazole naive aa 1,000 mg daily prednisone 5 mg b.i.d. 33 PSa ≥ 50% = 79% OR = 69% TTPP = 16.3 months Hypokalemia = 21% Hypertension = 18% Edema = 24% Phase III de Bono (2011) (ref.”
BackgroundInfluentialSelf-citationCastration Therapy Results in Decreased Ku70 Levels in Prostate Cancer
Al-Ubaidi, F. L. T., Schultz, N., Loseva, O., Egevad, L., Granfors, T., & Helleday, T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2795 · Cited by 74
“in treatment of castration-resistant prostate cancer (44, 45).”
BackgroundShiota, M., Yokomizo, A., & Naito, S. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0232 · Cited by 72
“…P17 inhibitor abiraterone acetate and the second-generation anti-androgen MDV3100 have been proved to reduce tumor burden and improve overall survival in CRPC patients, although their efficiencies are also limited, prolonging survival for only 3–5 months (de Bono et al. 2011, Scher et al. 2012).”
BackgroundResultABCB1 Mediates Cabazitaxel–Docetaxel Cross-Resistance in Advanced Prostate Cancer
Lombard, A. P., Liu, C., Armstrong, C. M., Cucchiara, V., Gu, X., Lou, W., Evans, C. P., & Gao, A. C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0179 · Cited by 76
Abiraterone acetate treatment lowers 11-oxygenated androgens
Wright, C., O’Day, P., Alyamani, M., Sharifi, N., & Auchus, R. J. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0905 · Cited by 68
“combination with prednisone has been shown to improve survival in CRPC patients (9, 10) as well as when added to ADT prior to the development of CRPC (11, 12).”
BackgroundHER3 Is an Actionable Target in Advanced Prostate Cancer
Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3360 · Cited by 68
“While these trials predated the identification of continued AR signaling as a cause of castration resistance, and clinical studies with abiraterone and enzalutamide (42), they discredited targeting ERBB signaling as a therapeutic strategy forCRPC.”
BackgroundSelf-citationProgress in emerging therapies for advanced prostate cancer
Oudard, S. M. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.09.005 · Cited by 81
Muscle and bone effects of androgen deprivation therapy: current and emerging therapies
Cheung, A. S., Zajac, J. D., & Grossmann, M. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0172 · Cited by 73
Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs
Rizzo, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188481 · Cited by 73
The evolving role of immune cells in prostate cancer
Wang, C., Zhang, Y., & Gao, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.027 · Cited by 81
Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin
Millis, S. Z., Bryant, D. H., Basu, G. D., Bender, R. P., Vranić, S., Gatalica, Z., & Vogelzang, N. J. (2014) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.07.010 · Cited by 72
Massari, F., Ciccarese, C., Caliò, A., Munari, E., Cima, L., Porcaro, A. B., Novella, G., Artibani, W., Sava, T., Eccher, A., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0396-3 · Cited by 72
“In recent years, the identification of various active agents for the treatment of metastatic castration-resistant prostate adenocarcinoma, including cytotoxic drugs (docetaxel and cabazitaxel) [15–17], hormone compounds (abiraterone acetate [18, 19] and enzalutamide [20, 21]), as well as particles emitting radionuclid…”
BackgroundRescigno, P., Lorente, D., Bianchini, D., Ferraldeschi, R., Kolinsky, M. P., Sideris, S., Zafeiriou, Z., Sumanasuriya, S., Smith, A. D., Mehra, N., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.055 · Cited by 70
“PSA response rates for the COU-301 and COU-302 trials were used for the postchemotherapy and prechemotherapy cohorts, respectively, as recently reported [21,22].”
MethodSelf-citationFerrari, A. C., Alumkal, J. J., Stein, M. N., Taplin, M., Babb, J. S., Barnett, E. S., Gómez-Pinillos, A., Liu, X., Moore, D. F., DiPaola, R. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1589 · Cited by 71
“Hemoglobin 1 (3) 2 (7) 3 (10) 3 (12) 0 (0) 3 (12)”
Taplin, M., Antonarakis, E. S., Ferrante, K. J., Horgan, K. E., Blumenstein, B. A., Fred Saad, C., Luo, J., & Bono, J. S. D. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.034 · Cited by 69
The role of adrenal derived androgens in castration resistant prostate cancer
Barnard, M., Mostaghel, E. A., Auchus, R. J., & Storbeck, K. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105506 · Cited by 70
“Phase I (36), II (31, 33) and III (34, 37) clinical studies with abiraterone have shown that the majority of patients respond well to abiraterone with primary outcomes including decreases in PSA levels (31, 33, 34, 36, 37, 171–173) along with a overall increase in patient survival compared to the placebo group (34, 37…”
Backgrounddu Toit, T., Bloem, L. M., Quanson, J. L., Ehlers, R., Serafin, A. M., & Swart, A. C. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.06.009 · Cited by 67
Thomsen, F. B., Røder, M. A., Rathenborg, P., Brasso, K., Borre, M., & Iversen, P. (2013) · Scandinavian Journal of Urology · doi:10.3109/21681805.2013.860189 · Cited by 71
“Both studies reported a modest response in this setting, with only 11% and 18% of patients experiencing a decrease in PSA of at least 30%, which is inferior to the PSA response reported for abiraterone administered post-chemotherapy without prior enzalutamide (COU-AA-301 trial) [5].”
BackgroundResultVignani, F., Bertaglia, V., Buttigliero, C., Tucci, M., Scagliotti, G. V., & Maïo, M. D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.002 · Cited by 74
“placebo plus prednisone in patients with metastatic CRPC (mCRPC) progressing after chemotherapy [51].”
Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?
Damodaran, S., Kyriakopoulos, C. E., & Jarrard, D. F. (2017) · Urologic Clinics of North America · doi:10.1016/j.ucl.2017.07.008 · Cited by 70
Groener, D., Nguyen, C. T., Baumgarten, J., Bockisch, B., Davis, K., Happel, C., Mader, N., Ngoc, C. N., Wichert, J., Banek, S., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00805-7 · Cited by 77
Current and emerging therapies for neuroendocrine prostate cancer
Alabi, B. R., Liu, S., & Stoyanova, T. I. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108255 · Cited by 76
Targeting molecular resistance in castration-resistant prostate cancer
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · BMC Medicine · doi:10.1186/s12916-015-0457-6 · Cited by 72
Zhu, Y., Liu, C., Armstrong, C. M., Lou, W., Sandher, A., & Gao, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0269 · Cited by 74
“Abiraterone inhibits intratumoral androgen biosynthesis by blocking CYP17A1 (8).”
Attard, G., Sydes, M. R., Mason, M. D., Clarke, N. W., Aebersold, D. M., Bono, J. S. D., Dearnaley, D. P., Parker, C. C., Ritchie, A. W. S., Russell, J. M., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.038 · Cited by 70
“Abiraterone has thus been developed for the treatment of metastatic castration-resistant prostate cancer (CRPC) in combination with prednisone or prednisolone [5].”
Progress and controversies: Radiation therapy for prostate cancer
Martin, N. E., & D'Amico, A. V. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21250 · Cited by 82
Darolutamide (ODM-201) for the treatment of prostate cancer
Shore, N. D. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1329820 · Cited by 68
COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature
Lorenzo, G. D., Trolio, R. D., Kozlakidis, Z., Busto, G., Ingenito, C., Buonerba, L., Ferrara, C., Libroia, A., Ragone, G., Ioio, C. D., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102991 · Cited by 67
Kyriakopoulos, C. E., Eickhoff, J. C., Ferrari, A. C., Schweizer, M. T., Wargowski, E., Olson, B. M., & McNeel, D. G. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0945 · Cited by 68
Circulating tumor cell profiling for precision oncology
Labib, M., & Kelley, S. O. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12901 · Cited by 73
AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
Sobhani, N., Neeli, P. K., D’Angelo, A., Pittacolo, M., Sirico, M., Galli, I. C., Roviello, G., & Nesi, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115515 · Cited by 74
“synthesis (abiraterone acetate) and androgen receptor (enzalutamide) following favorable Phase III trial results [8,9].”
BackgroundInfluentialPTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications
Choudhury, A. D. (2022) · The Prostate · doi:10.1002/pros.24372 · Cited by 83
Garje, R., Riaz, I. B., Naqvi, S. A. A., Rumble, R. B., Taplin, M., Kungel, T. M., Herchenhorn, D., Zhang, T., Beckermann, K. E., Vapiwala, N., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00007 · Cited by 89
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Rodríguez‐Vida, A., Chowdhury, S., Sternberg, C. N., Rudman, S. M., & Galazi, M. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s69433 · Cited by 77
Self-citationMukherji, D., Omlin, A. G., Pezaro, C. J., Shamseddine, A. I., & Bono, J. S. D. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9473-1 · Cited by 67
“Treatments proven to improve OS in men with symptomatic CRPC include docetaxel, cabazitaxel, abiraterone, enzalutamide, and radium-223 (see Tables 1 and 3) [5, 6, 8, 9, 24].”
BackgroundWang, L., Wang, J., Xiong, H., Wu, F., Lan, T., Zhang, Y., Guo, X., Wang, H., Saleem, M., Jiang, C., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.022 · Cited by 67
Carton, E., Noé, G., Huillard, O., Golmard, L., Giroux, J., Cessot, A., Saidu, N. E. B., Peyromaure, M., Zerbib, M., Narjoz, C., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.11.027 · Cited by 68
“ABI plus low-dose prednisone was first shown to improve survival in mCRPC patients pre-treated with docetaxel, and the combination therapy has since been approved for this purpose [6,7].”
BackgroundLu‐Yao, G. L., Nikita, N., Keith, S. W., Nightingale, G., Gandhi, K., Hegarty, S., Rebbeck, T. R., Chapman, A. E., Kantoff, P. W., Cullen, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.07.031 · Cited by 67
“However, pivotal trials of AA excluded men with clinically significant cardiovascular disease (CVD) conditions or serious coexisting nonmalignant disease [2], or uncontrolled hypertension; likewise, pivotal trials of ENZ excluded patients with significant comorbidities [3].”
BackgroundThe role of epithelial plasticity in prostate cancer dissemination and treatment resistance
Bitting, R. L., Schaeffer, D., Somarelli, J. A., García-Blanco, M. A., & Armstrong, A. J. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9483-z · Cited by 71
Maughan, B. L., Luber, B. S., Nadal, R., & Antonarakis, E. S. (2016) · The Prostate · doi:10.1002/pros.23246 · Cited by 66
Ruiz de Porras, V., Font, A., & Aytes, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.033 · Cited by 65
Cancer stem cell in prostate cancer progression, metastasis and therapy resistance
Verma, P., Shukla, N., Kumari, S., Ansari, M. S., Gautam, N. K., & Patel, G. K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188887 · Cited by 70
Shiota, M., Zoubeidi, A., Kumano, M., Beraldi, E., Naito, S., Nelson, C. C., Sorensen, P. H. B., & Gleave, M. E. (2011) · The Journal of Urology · doi:10.1016/j.juro.2012.02.550 · Cited by 68
Chen, M., Adeniji, A. O., Twenter, B. M., Winkler, J. D., Christianson, D. W., & Penning, T. M. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.085 · Cited by 65
Use of androgen deprivation therapy in prostate cancer: indications and prevalence
Connolly, R. M., Carducci, M. A., & Antonarakis, E. S. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.103 · Cited by 70
Saad, E. D., & Buyse, M. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6359 · Cited by 71
Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond
Nakazawa, M., & Kyprianou, N. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.05.007 · Cited by 72
“Abiraterone and enzalutamide, two potent androgen receptor (AR) signaling inhibitors currently deployed as standard-of-care CRPC therapies, offer improvements of four and five months respectively in terms of overall survival [14,15].”
BackgroundZhan, Y., Zhang, G., Wang, X., Qi, Y., Bai, S., Li, D., Ma, T., Sartor, O. A., Flemington, E. K., Zhang, H., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0236 · Cited by 68
Wilkerson, J., Abdallah, K. A., Hugh-Jones, C., Curt, G., Rothenberg, M. L., Simantov, R., Murphy, M., Morrell, J., Beetsch, J., Sargent, D. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30633-7 · Cited by 75
Self-citationTherapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
Ulm, M. A., Ramesh, A. V., McNamara, K. M., Ponnusamy, S., Sasano, H., & Narayanan, R. (2019) · Endocrine Connections · doi:10.1530/ec-18-0425 · Cited by 73
Crespo, M., van Dalum, G., Ferraldeschi, R., Zafeiriou, Z., Sideris, S., Lorente, D., Bianchini, D., Rodrigues, D. N., Riisnaes, R., Miranda, S., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.63 · Cited by 67
“Although targeting of the androgen receptor (AR) with abiraterone or enzalutamide improves survival in CRPC (de Bono et al, 2011; Scher et al, 2012), resistance invariably develops and the response rate to sequential treatment appears lower when one agent is used after the other (Loriot et al,…”
BackgroundSelf-citation
Metadata
- Authors
- de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., & Scher, H. I.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
- Cross Cancer Institute (CA)
- BC Cancer Agency (CA)
- University of Glasgow (GB)
- Institute of Cancer Research (GB)
- Velindre Cancer Centre (GB)
- University College London (GB)
- University of Colorado Cancer Center (US)
- University of Calgary (CA)
- University of California, San Francisco (US)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Centre Léon Bérard (FR)
- Georgia Cancer Specialists (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Logothetis, Christopher J.
- Molina, Arturo
- Fizazi, Karim
- North, Scott
- Chi, Kim N.
- Jones, Robert J.
- Goodman, Oscar B.
- Staffurth, John N.
- Mainwaring, Paul
- Flaig, Thomas W.
- Hutson, Thomas E.
- Cheng, Tina
- Hainsworth, John D.
- Ryan, Charles J.
- Sternberg, Cora N.
- Ellard, Susan L.
- Fléchon, Aude
- Saleh, Mansoor
- Efstathiou, Eleni
- Bianchini, Diletta
- Loriot, Yohann
- Kheoh, Thian
- Haqq, Christopher M.
- Scher, Howard I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-26
- Volume
- 364
- Issue
- 21
- Pages
- 1995-2005
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3471149
- OpenAlex
- W2110534364
- Cited by
- 4,407
- References
- 54
- Citations by year
- 2026: 111 · 2025: 184 · 2024: 187 · 2023: 209 · 2022: 235 · 2021: 287 · 2020: 290 · 2019: 299 · 2018: 332 · 2017: 322 · 2016: 342 · 2015: 352 · 2014: 384 · 2013: 403 · 2012: 347
- FWCI
- 336.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Les Laboratories Pierre Fabre
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research
- Astellas Pharma
- Genentech
- Foundation Medicine
- Medical Research Council
- National Cancer Institute (P50CA092629)
- Cilag
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- abiraterone, metastatic castration-resistant prostate cancer, androgen biosynthesis inhibition, overall survival, docetaxel, prednisone, prostate-specific antigen progression, progression-free survival, fluid retention, hypokalemia, hypertension
- MeSH terms
- Aged, Androgen Antagonists, Androgens, Androstenes, Androstenols, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Fatigue, Humans, Male, Middle Aged, Neoplasm Metastasis, Prednisone, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Survival Analysis, Treatment Outcome, Disease Progression, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.